Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Metsera’s (NASDAQ:MTSR – Get Free Report) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its initial public offering on January 31st. The total size of ...

A Quick Take On Metsera, Inc. Metsera, Inc. (NASDAQ:MTSR) has filed to raise $275 million in an IPO of its common stock, according to SEC S-1/A registration information. The firm is a clinical ...

During the IPO, two investors acquired $25.78 million worth of Metsera shares each, at a price of $18 per share. Currently, the stock is trading at $28.50 per share, having gained 7.55% since the IPO.

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.

Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...